{
    "clinical_study": {
        "@rank": "1577", 
        "arm_group": {
            "arm_group_label": "MPH or Placebo", 
            "arm_group_type": "Experimental", 
            "description": "MPH dosage will be determined according to participants' body weight: dosage: 10 mg in case weight<40 kg; 30 mg in case weight>90 kg; otherwise 20 mg.  Both participants and investigators will be blinded to when participant receives MPH or Placebo."
        }, 
        "brief_summary": {
            "textblock": "The purpose of the study is to explore the effect of MPH on working memory, attention and\n      decision making in adults with BD in remission or in depressed state.  The results will be\n      compared to findings in healthy adults and adults with ADHD.  The investigators hypothesize\n      that MPH will incur improved performance in all measures."
        }, 
        "brief_title": "The Effect of Methylphenidate on Cognitive Abilities of Adults With Bipolar Disorder", 
        "condition": "BD", 
        "condition_browse": {
            "mesh_term": [
                "Bipolar Disorder", 
                "Attention Deficit Disorder with Hyperactivity"
            ]
        }, 
        "detailed_description": {
            "textblock": "Following a detailed explanation about the trial and after obtaining informed consent from\n      candidates, subjects will be asked to arrive at the cognitive laboratory at Shalvata MHC\n      twice.  Visits will include performance of computerized cognitive and decision making tasks,\n      as well as two creativity tasks after the consumption of MPH or placebo."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Hebrew Speakers\n\n          -  Age 21-50\n\n          -  Diagnosis of BD I or II (296.7 and 296.89 classifications in the DSM-IV-TR),\n             according to medical records.  Diagnosis will be confirmed by a psychiatrist during\n             screening process using the Structured Clinical Interview for DSM-IV-TR (SCID).\n\n        Exclusion Criteria:\n\n          -  Diagnosis of a clinical disorder other than BD or ADD/ADHD which may impair\n             performance on tasks used in the study.\n\n          -  BD patients diagnosed with an acute manic episode at screening, as established by\n             YMRS>8.  It will also be required that 3 months have elapsed since the latest manic\n             state, according to the patients' history.\n\n          -  Participants for whom there exists a contra-indication for consuming Ritalin.\n\n          -  Pregnancy or current breastfeeding; Female participants will be asked to report\n             whether they are pregnant or currently nursing and if so, they will be excluded from\n             the study.\n\n          -  Drug use in the previous 6 weeks according to participants' self report\n\n          -  Electroconvulsive therapy (ECT) in the previous 6 months"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "50 Years", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02020200", 
            "org_study_id": "0021-12-SHA"
        }, 
        "intervention": [
            {
                "arm_group_label": "MPH or Placebo", 
                "description": "MPH dosage will be determined according to participants' body weight: dosage: 10 mg in case weight<40 kg; 30 mg in case weight>90 kg; otherwise 20 mg.", 
                "intervention_name": "MPH", 
                "intervention_type": "Drug", 
                "other_name": "Ritalin"
            }, 
            {
                "arm_group_label": "MPH or Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Methylphenidate"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Bipolar Disorder", 
            "Methylphenidate", 
            "Cognitive Function"
        ], 
        "lastchanged_date": "December 23, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Hod HaSharon", 
                    "country": "Israel"
                }, 
                "name": "Shalvata MHC"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Israel"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Crossover Study on the Effect of Methylphenidate (MPH) on Cognitive Abilities of Adults With Bipolar Disorder (BD), During Remission or Depressed State, Compared With Healthy Adults and Adults With Attention Deficit Hyperactivity Disorder (ADHD).", 
        "overall_contact": {
            "email": "yaelle4@clalit.org.il", 
            "last_name": "Yael Lewis, MD", 
            "phone": "+97297478644"
        }, 
        "overall_contact_backup": {
            "last_name": "Yechiel Levkovitz, MD, PhD", 
            "phone": "+97297478644"
        }, 
        "overall_official": {
            "affiliation": "Shalavata MHC", 
            "last_name": "Yechiel Levkovitz, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Israel: Ministry of Health"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Cognitive function will be measured by scores on several computerized neuro-psychological and decision making tasks: digit-span task, spatial working memory task, raven's progressive matrices, test of variable attention and the Iowa gambling task.", 
            "measure": "Cognitive function.", 
            "safety_issue": "No", 
            "time_frame": "Within 4 hours of intervention."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02020200"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Creativity will be measured by scores on two tests: the alternative use task and two subsets of the Torrance tests for creative thinking.", 
            "measure": "Creativity abilities.", 
            "safety_issue": "No", 
            "time_frame": "Within 4 hours of intervention."
        }, 
        "source": "Shalvata Mental Health Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Shalvata Mental Health Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}